Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma

Modern Pathology

Volumn 25, Issue 4, 2012, Pages 625-636

  Soslow, Robert A ^a   Han, Guangming ^b   Park, Kay J ^a   Garg, Karuna ^a   Olvera, Narciso ^a   Spriggs, David R ^a   Kauff, Noah D ^a   Levine, Douglas A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

BRCA; endometrioid carcinoma; hereditary ovarian cancer; morphology; phenotype; serous carcinoma; transitional cell carcinoma; tumor infiltrating lymphocytes

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ALGORITHM; ARTICLE; CANCER CENTER; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DNA METHYLATION; ENDOMETRIOID CARCINOMA; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENOME; GENOTYPE; HUMAN; HUMAN TISSUE; HYPOTHESIS; INFORMATION PROCESSING; MITOSIS INDEX; OVARY CARCINOMA; PILOT STUDY; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROMOTER REGION; RANDOMIZATION; SENSITIVITY AND SPECIFICITY; SOMATIC MUTATION; STATISTICAL SIGNIFICANCE; TISSUE SECTION; TRANSITIONAL CELL CARCINOMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR NECROSIS; UTERINE TUBE;

ALGORITHMS; BRCA1 PROTEIN; BRCA2 PROTEIN; CARCINOMA; CASE-CONTROL STUDIES; CELL NUCLEUS; DNA METHYLATION; DNA MUTATIONAL ANALYSIS; FALLOPIAN TUBES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MITOTIC INDEX; MUTATION; NECROSIS; NEOPLASM GRADING; NEW YORK CITY; OVARIAN NEOPLASMS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROMOTER REGIONS, GENETIC;

EID: 84857555621     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.183     Document Type: Article

References (34)

1. Risch HA, McLaughlin JR, Cole DEC, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001;68:700-710. (Pubitemid 32203724)
2. Press JZ, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008;8:17.
3. Husain A, He G, Venkatraman ES, et al. BRCA1 upregulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 1998;58:1120-1123. (Pubitemid 28183195)
4. Yuan SS, Lee SY, Chen G, et al. BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res 1999;59:3547-3551. (Pubitemid 29381849)
5. Ben David Y, Chetrit A, Hirsh-Yechezkel G, et al. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 2002;20: 463-466. (Pubitemid 34072530)
6. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000;283:2260-2265. (Pubitemid 30246777)
7. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-251.
8. Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proofof-concept trial. Lancet 2010;376:235-244.
9. Fong PC, Yap TA, Boss DS, et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 2010;28:2512-2519.
10. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8 +regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005;102:18538-18543. (Pubitemid 43011261)
11. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Eng J Med 2003;348:203-213. (Pubitemid 36077915)
12. Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007;104:3360-3365. (Pubitemid 46364164)
13. Clarke B, Tinker AV, Lee CH, et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 2009;22:393-402.
14. Robey SS, Silva EG, Gershenson DM, et al. Transitional cell carcinoma in high-grade high-stage ovarian carcinoma. An indicator of favorable response to chemotherapy. Cancer 1989;63:839-847. (Pubitemid 19063188)
15. Gershenson DM, Silva EG, Mitchell MF, et al. Transitional cell carcinoma of the ovary: a matched control study of advanced-stage patients treated with cisplatin-based chemotherapy. Am J Obstet Gynecol 1993;168:1178-1187. (Pubitemid 23122168)
16. Kommoss F, Kommoss S, Schmidt D, et al. Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel. Gynecol Oncol 2005;97:195-199. (Pubitemid 40403694)
17. Tisserand P, Fouquet C, Barrois M, et al. Lack of HIN-1 methylation defines specific breast tumor subtypes including medullary carcinoma of the breast and BRCA1-linked tumors. Cancer Biol Ther 2003;2: 559-563.
18. Armes JE, Egan AJM, Southey MC, et al. The histologic phenotypes of breast carcinoma occurring before ageyears in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 1998;83:2335-2345 (Pubitemid 28533503)
19. Lakhani SR, Gusterson BA, Jacquemier J, et al. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 2000;6:782-789. (Pubitemid 30159330)
20. Wong EM, Southey MC, Fox SB, et al. Constitutional methylation of the BRCA1 promoter is specifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. Cancer Prev Res 2011;4: 23-33.
21. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-615.
22. Gilks CB, Ionescu DN, Kalloger SE, et al. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. Hum Pathol 2008;39:1239-1251.
23. Eichhorn JH, Young RH. Transitional cell carcinoma of the ovary: a morphologic study of 100 cases with emphasis on differential diagnosis. Am J Surg Pathol 2004;28:453-463. (Pubitemid 38436518)
24. Rubin SC, Benjamin I, Behbakht K, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996;335: 1413-1416. (Pubitemid 26382501)
25. Takahashi H, Behbakht K, McGovern PE, et al. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res 1995;55:2998-3002.
26. Roh MH, Yassin Y, Miron A, et al. High-grade fimbrialovarian carcinomas are unified by altered p53, PTEN and PAX2 expression. Mod Pathol 2010;23: 1316-1324.
27. Takahashi H, Chiu HC, Bandera CA, et al. Mutations of the BRCA2 gene in ovarian carcinomas. Cancer Res 1996;56:2738-2741. (Pubitemid 26175729)
28. Werness BA, Ramus SJ, DiCioccio RA, et al. Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry. Int J Gynecol Pathol 2004; 23:29-34. (Pubitemid 38018234)
29. Lakhani SR, Manek S, Frederique Penault-Llorca F, et al. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res 2004;10:2473-2481. (Pubitemid 38445709)
30. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000;283:2260-2265. (Pubitemid 30246777)
31. Logani S, Oliva E, Amin MB, et al. Immunoprofile of ovarian tumors with putative transitional cell (urothelial) differentiation using novel urothelial markers: histogenetic and diagnostic implications. Am J Surg Pathol 2003;27:1434-1441. (Pubitemid 37315195)
32. Wu R, Hendrix-Lucas N, Kuick R, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/b-catenin and PI3K/Pten signaling pathways. Cancer Cell 2007;11:321-333. (Pubitemid 46518315)
33. Soslow RA. Histologic subtypes of ovarian carcinoma: an overview. Int J Gynecol Pathol 2008;27: 161-174. (Pubitemid 351450675)
34. Köbel M, Kalloger SE, Baker PM, et al. Diagnosis of ovarian carcinoma cell type is highly reproducible: a Trans-Canadian study. Am J Surg Pathol 2010;34: 984-993.